Stay updated on Nivolumab+Ipilimumab in Limited-Stage Small Cell Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Limited-Stage Small Cell Lung Cancer Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab in Limited-Stage Small Cell Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedAdded Revision: v3.3.3; removed HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed, which appears to be an internal version update with no impact on study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check39 days agoChange DetectedThe government funding lapse and operating-status disclaimer at the top of the page has been removed.SummaryDifference0.2%

- Check53 days agoChange DetectedBoth screenshots show the same study details page with no added or removed content or layout changes.SummaryDifference0.3%

- Check82 days agoChange Detected- Added a government funding notice and current operating status guidance, and updated the version to v3.2.0. - Removed the Genetic and Rare Diseases Information Center resource for Small cell lung carcinoma and old version reference v3.1.0.SummaryDifference2%

- Check89 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.0%

Stay in the know with updates to Nivolumab+Ipilimumab in Limited-Stage Small Cell Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Limited-Stage Small Cell Lung Cancer Clinical Trial page.